tbuckley/cabot-search huggingface dataset:
Thyroid Cancer: Risk-Stratified Management and Individualized Therapy
Authors: Friedhelm Raue, Karin Frank-Raue
Journal: Clinical Cancer Research (2016)

Thyroid cancer is the most common endocrine malignancy. Differentiated thyroid cancer (DTC) with the two subtypes, papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC), is the most frequent subtype of thyroid cancer; more rare subtypes are medullary thyroid cancer (MTC) and anaplastic thyroid cancer (ATC). The incidence of DTC has increased rapidly in recent years due to the more frequent use of imaging methods such as ultrasound of the neck and fine-needle aspiration (FNA) of thyroid nodules. After total thyroidectomy and radioiodine treatment, DTC remains an indolent and curable disease in most patients, whereas the cure rate in MTC is lower and depends on early diagnosis. Most ATCs are incurable. In recent years, there has been great progress in identifying genetic changes in thyroid cancer, and genetic testing of FNA samples or blood samples provides useful information for clinical decision making. Tumor staging, either postoperatively or by imaging, and measuring the tumor markers thyroglobulin for DTC and calcitonin for MTC, allow for dynamic risk-adapted stratification for follow-up procedures. In advanced metastatic thyroid cancer, molecular targeted therapy using tyrosine kinase receptor inhibitors, including sorafenib, lenvantinib, vandetanib, and cabozantinib, helps control tumor progression and prolongs progression-free survival. Using a dynamic risk-stratified approach to manage thyroid cancer, the outcomes for most thyroid cancer patients are excellent compared with those for other cancers. The major challenge in the future is to identify high-risk patients and to treat and monitor them appropriately. Clin Cancer Res; 22(20); 5012-21. ©2016 AACR SEE ALL ARTICLES IN THIS CCR FOCUS SECTION, "ENDOCRINE CANCERS REVISING PARADIGMS".
Virologic, Clinical, and Immune Response Outcomes of Patients With Hepatitis C Virus–Associated Cryoglobulinemia Treated With Direct-Acting Antivirals
Authors: Martín Bonacci, Sabela Lens, María-Carlota Londoño, Zoe Mariño, Maria C. Cid, Manuel Ramos-Casals, Jose María Sánchez-Tapias, Xavier Forns, José Hernández-Rodríguez
Journal: Clinical Gastroenterology and Hepatology (2016)
Introduction to the Theme “New Methods and Novel Therapeutic Approaches in Pharmacology and Toxicology”
Authors: Paul A. Insel, Susan G. Amara, Terrence F. Blaschke, Urs A. Meyer
Journal: The Annual Review of Pharmacology and Toxicology (2016)

Major advances in scientific discovery and insights can result from the development and use of new techniques, as exemplified by the work of Solomon Snyder, who writes a prefatory article in this volume. The Editors have chosen "New Methods and Novel Therapeutic Approaches in Pharmacology and Toxicology" as the Theme for a number of articles in this volume. These include ones that review the development and use of new experimental tools and approaches (e.g., nanobodies and techniques to explore protein-protein interactions), new types of therapeutics (e.g., aptamers and antisense oligonucleotides), and systems pharmacology, which assembles (big) data derived from omics studies together with information regarding drugs and patients. The application of these new methods and therapeutic approaches has the potential to have a major impact on basic and clinical research in pharmacology and toxicology as well as on patient care.
TCT-53 Left Atrial Appendage Occlusion in Patients with Atrial Fibrillation and Intracranial Bleeding: Results from the Amplatzer Cardiac Plug Registry
Authors: Apostolos Tzikas, Xavier Freixa, Sameer Gafoor, George Giannakoulas, Samera Shakir, Heyder Omran, Sergio Berti, Gennaro Santoro, Joelle Kefer, Adel Aminian, Ulf Landmesser, Jens Erik Nielsen-Kudsk, Ignacio Cruz-González, Prapa Kanagaratnam, Fabian Nietlispach, Reda Ibrahim, Wolfgang Schillinger, Bernhard Meier, Jai-Wun Park, Horst Sievert, Haralampos Karvounis
Journal: Journal of the American College of Cardiology (2015)
No Adverse Effects After Radioiodine Treatment at 3 Weeks of Pregnancy
Authors: Matea Radacic-Aumiler, Iva Kraljickovic, Viktorija Edeljic-Turk, Ksenija Makar-Ausperger, Robert Likic, Iveta Simic
Journal: Clinical Nuclear Medicine (2016)

Radioactive iodine is used for the treatment of hyperthyroidism. Because it accumulates in the fetal thyroid, its administration during pregnancy may cause severe and potentially irreversible hypothyroidism in neonates, with consequent mental retardation, and it is contraindicated during the whole pregnancy. We present a case of a pregnant woman inadvertently treated with 1 mCi (37 MBq) of I in the earliest period of pregnancy and subsequently gave birth to a male infant without signs or symptoms of hypothyroidism or any other damage. This case illustrates that when radioactive iodine administration happens around the third week of gestation pregnancy outcome can be normal.
Chemosensitisation of cancer cells by KU-0060648, a potent and selective inhibitor of DNA-PK [abstract]
Authors: Michael Batey, Yan Zhao, Kerry Shea, Julia Bardos, Caroline Richardson, Helen Jenkins, Andrew Slade, Aaron Cranston, Roger Griffin, David Newell, Graeme Smith, Mark Albertella, Nicola Curtin
Journal: Cancer Research (2008)

4080  DNA double strand breaks (DSB) are profoundly cytotoxic unless rapidly repaired. Non-homologous end joining (NHEJ) is the predominant pathway of repair in mammalian cells. DNA-dependent protein kinase (DNA-PK), a member of the PI3-kinase like kinase (PIKK) family, is an essential component of NHEJ. DNA-PK inhibition is therefore an attractive target for radio- and chemosensitisation in cancer therapy.  We have developed a series of DNA-PK inhibitors of increasing potency culminating in KU-0060648, IC50 = 8.6 nM with 20-1000-fold selectivity for DNA-PK over other PIKKs and a panel of 60 kinases. At non-cytotoxic concentrations KU-0060648 (≤ 1 μM) increased the cytotoxicity of the topoisomerase II poisons, doxorubicin and etoposide, in a panel of human cancer cell lines. Potentiation of 100 nM doxorubicin cytotoxicity ranged from 3-fold in MDA-MB-231 cells to 107-fold in MCF7 cells and potentiation of 1 μM etoposide cytotoxicity ranged from 3-fold in MDA-MB-231 cells to 105-fold in SW620 cells. KU-0060648 increased doxorubicin-dependent H2AX phosphorylation, consistent with increased DNA damage resulting in cytotoxicity. Studies in DNA-PK proficient and deficient cells demonstrated that chemo and radio-sensitisation by KU-0060648 was DNA-PK specific.  KU-0060648 has been administered i.v. (25 mg/kg), i.p. (25 mg/kg) and p.o (100 mg/kg) to mice without adverse toxicity. Plasma and tissue pharmacokinetic studies show that tumour levels commensurate with sensitisation in vitro can be maintained for at least 4 hours following administration of 10 mg/kg i.p. KU-0060648 showed 100% bioavailability by oral administration at 10mg/kg, and a t1/2 of >2h. Pharmacodynamic assays demonstrate inhibition of DNA-PK activity in tumours. In mice bearing SW620 xenografts the etoposide (10 mg/kg dailyx5)-induced tumour growth delay of 0.5 days was significantly extended to 5 days by KU-0060648 (10 mg/kg 2xdailyx5).  In conclusion, KU-0060648 is a potent and selective DNA-PK inhibitor. It has acceptable PK and DNA-PK is inhibited in target tissues at tolerable doses. It is a potent chemosensitiser in models of common human malignancies in vitro and in vivo.
A phase II study of intravenous reolysin (wild-type reovirus) in the treatment of patients with bone and soft tissue sarcomas metastatic to the lung
Authors: S. A. Soefje, J. Sarantopoulos, K. K. Sankhala, A. C. Mita, J. J. Mahany Jr., T. Carmona, M. Coffey, G. M. Gill, K. Mettinger, M. M. Mita
Journal: Journal of Clinical Oncology (2008)

10568 Background: Reolysin (reovirus serotype 3) is a Dearing strain, naturally occurring, ubiquitous, non-enveloped human reovirus. The community-acquired infection is mild and limited to the upper respiratory and GI tract. The virus inhibits the double-stranded RNA- activated protein kinase (PKR) and replicates specifically in transformed cells possessing an activated Ras pathway producing lysis. In in vitro and in vivo studies in Ewing’s sarcoma, rhabdomyosarcoma, synovial sarcoma, and osteosarcoma cell lines revealed significant antitumor activity. Methods: This phase II open-label, single agent study was designed to characterize the efficacy and safety of reolysin given IV every 28 days (4 weeks) in patients (pts) with bone or soft tissue sarcoma with lung metastasis using a Simon two-stage design. 14 pts will be enrolled in the first stage and up to a total of 56 pts in the second stage if at least 1 pt in the first stage experiences partial response or stable disease for at least 6 months. Results: Since July 2007, 10 pts (pts) age 28 -70 (median 51) were enrolled (6 females and 4 males) and received a total of 23 cycles (range 2–5). The tumor types included malignant fibrous histiocytoma 3 pts, osteosarcoma 3 pts, leiomyosarcoma 2 pts, synovial sarcoma 1 pt, and undifferentiated round cell sarcoma 1 pt. All pts had performance status 1 (7 pts) or 0 (3 pts). Eight pts received prior chemotherapy, radiotherapy, biologic agents or combinations for their metastatic disease. Side effects were mild to moderate (grade 1–2) and included mainly constitutional symptoms fever, chills, arthralgia, fatigue in all pts. Two pts experienced respiratory side effects such as cough and SOB and 2 pts had diarrhea. Hematologic side effects were rare and included grade 2–3 neutropenia (3 pts) and grade 2 thrombocytopenia (2 pts). One pt experienced grade 2 AST elevation. 8 pts are evaluable for response to date: 3 pts had SD (5+, 4 and 2+ months). Four pts had PD. Two pts are too early in the study for tumor evaluation. Conclusions: Reolysin is well tolerated and shows promise for the treatment of metastatic sarcoma. Accrual is ongoing. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Oncolytics Biotech, Inc. Oncolytics Biotech, Inc Oncolytics Biotech, Inc
Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non–Small Cell Lung Cancer
Authors: Suresh S. Ramalingam, Normand Blais, Julien Mazieres, Martin Reck, C. Michael Jones, Erzsebet Juhasz, Laszlo Urban, Sergey Orlov, Fabrice Barlesi, Ebenezer Kio, Ulrich Keiholz, Qin Qin, Jiang Qian, Caroline Nickner, Juliann Dziubinski, Hao Xiong, Peter Ansell, Mark McKee, Vincent Giranda, Vera Gorbunova
Journal: Clinical Cancer Research (2016)

Purpose: PARP plays an important role in DNA repair. Veliparib, a PARP inhibitor, enhances the efficacy of platinum compounds and has been safely combined with carboplatin and paclitaxel. The primary endpoint of this phase II trial determined whether addition of veliparib to carboplatin and paclitaxel improved progression-free survival (PFS) in previously untreated patients with advanced/metastatic non-small cell lung cancer.Experimental Design: Patients were randomized 2:1 to carboplatin and paclitaxel with either veliparib or placebo. Veliparib (120 mg) or placebo was given on days 1 to 7 of each 3-week cycle, with carboplatin (AUC = 6 mg/mL/min) and paclitaxel (200 mg/m2) administered on day 3, for a maximum of 6 cycles.Results: Overall, 158 were included (median age, 63 years; male 68%, squamous histology 48%). Median PFS was 5.8 months in the veliparib group versus 4.2 months in the placebo group [HR, 0.72; 95% confidence interval (CI), 0.45-1.15; P = 0.17)]. Median overall survival (OS) was 11.7 and 9.1 months in the veliparib and placebo groups, respectively (HR, 0.80; 95% CI, 0.54-1.18; P = 0.27). In patients with squamous histology, median PFS (HR, 0.54; 95% CI, 0.26-1.12; P = 0.098) and OS (HR, 0.73; 95% CI, 0.43-1.24; P = 0.24) favored veliparib treatment. Objective response rate was similar between groups (veliparib: 32.4%; placebo: 32.1%), but duration of response favored veliparib treatment (HR, 0.47; 95% CI, 0.16-1.42; P = 0.18). Grade III/IV neutropenia, thrombocytopenia, and anemia were comparable between groups.Conclusions: Veliparib combination with carboplatin and paclitaxel was well-tolerated and demonstrated a favorable trend in PFS and OS versus chemotherapy alone. Patients with squamous histology had the best outcomes with veliparib combination. Clin Cancer Res; 23(8); 1937-44. ©2016 AACR.
The principles and practice of nutritional support
Authors: Simon Lal
Journal: Gut (2016)

Stephen JD O'Keefe. Spring-Verlag New York Inc. New York, USA. ISBN: 1493917781.

This book provides exactly what it says on the cover: a useful practical guide for multidisciplinary health professionals in nutrition support. It is, of course, strengthened by the expertise and reputation of Dr O'Keefe in the field, and I agree with Dr O'Keefe that the book's single authorship avoids overlap and allows focus on the common principles of nutritional support that are applicable to various disease states.

The book is divided into three parts: ‘the principles' and ‘the practice’ of general nutrition support and a final part that reviews nutritional support in different diseases, along with a succinct overview of the more complex conditions of intestinal failure and small bowel transplantation.

Part …
TCT-564 Clinical Predictors of Target Lesion Revascularization after SES or EES implantation
Authors: Seiichi Hiramori, Hirotoshi Watanabe, Hiroki Shiomi, Ken Kozuma, Takeshi Morimoto, Keiichi Igarashi, Kazushige Kadota, Kengo Tanabe, Yoshihiro Morino, Shinichi Shirai, Kenji Ando, Masakiyo Nobuyoshi, Takeshi Kimura
Journal: Journal of the American College of Cardiology (2015)
GW27-e0779 Effects of Combined Infusion of Fibroblast Growth Factor 2 and Bone Marrow Mesenchymal Stem Cells via Coronary Veins on Ventricular Remodeling in a Canine Infarct Model
Authors: Xiao Wang, Lei Zhen, Huangtai Miao, Qiwei Sun, Ya Yang, Xingxin Wu, Shutian Shi, Shaoping Nie
Journal: Journal of the American College of Cardiology (2016)
Knockdown (KD) of Mir-126 Expression Enhances Tyrosine Kinase Inhibitor (TKI)-Mediated Targeting of Chronic Myelogenous Leukemia (CML) Stem Cells
Authors: Bin Zhang, Ling Li, Ching-Cheng Chen, Anthony S. Stein, Haris Ali, David S. Snyder, Allen Lin, Adrienne Dorrance, Piotr Swiderski, Ravi Bhatia, Danilo Perrotti, Stephen J. Forman, Ya-Huei Kuo, Marcin Kortylewski, Guido Marcucci
Journal: Blood (2015)
GW27-e0482 Relationship between pre-operative plasma lipoprotein-associated phospholipase A2 levels and recurrence of atrial fibrillation in patients after catheter ablation
Authors: Zhenguang Li, Hairong Sun, Duanlan Ma, Pengfei Wang, Jiangshan Zhang, Zhancai Yu, Jinbiao Zhang
Journal: Journal of the American College of Cardiology (2016)
Small Bowel Carcinoid
Authors: Mehdi Helali, Céline Heimburger, Serge Rohr, Bernard Goichot, Alessio Imperiale
Journal: Clinical Nuclear Medicine (2016)

The localization of small bowel (SB) neuroendocrine tumors (NETs) remains a diagnostic challenge in clinical practice. In about a third of cases, SB-NETs are multiple at diagnosis. However, the sensitivity of conventional presurgical diagnostic investigations is not exhaustive. 18F-FDOPA (6-L-18F-fluorodihydroxyphenylalanine) PET seems to be a valuable diagnostic technique for the detection of midgut NETs. According to our experience, a delayed PET/CT acquisition centered on abdominopelvic region and performed after oral hydration may improve the detection of primary tumor and the identification of patients with multifocal SB-NETs who could benefit from a more accurate intraoperative palpation of the entire SB.
TCT-33 Left Atrial Decompression with the V-Wave Shunt Device for the Treatment of Heart Failure: Preliminary Safety and Efficacy Results
Authors: Maria Del Trigo, Sebastien Bergeron, Mathieu Bernier, Ignacio J. Amat-Santos, Francisco Campelo-Parada, Omar Abdul-Jawad Altisent, Philippe Pibarot, Neal Eigler, Frank Litvack, Rotem Katzenellenbogen, Lior Rosen, Erez Rozenfeld, William Abraham, Josep Rodes-Cabau
Journal: Journal of the American College of Cardiology (2015)
TCT-48 Early vascular responses to everolimus-eluting cobalt-chromium stent for the treatment of stable coronary artery disease: The results of MECHANISM-Elective 1-month OCT follow-up cohort
Authors: Toshiro Shinke, Hiromasa Otake, Daisuke Terashita, Tetsuya Fusazaki, Tatsuo Kikuchi, Takayuki Okamura, Takashi Morita, Takahiro Sawada, Akira Matsuura, Yoshinori Yasaka, Amane Kozuki, Junya Shite, Toru Kataoka, Kiyoshi Hibi, Shozo Ishihara, Takashi Akasaka, Takashi Kubo, Shinjo Sonoda, Jungo Furuya, Teppei Sugaya, Yoshisato Shibata, Nehiro Kuriyama, Daisuke Matsumoto, Yoritaka Otsuka, Yoshihiro Morino
Journal: Journal of the American College of Cardiology (2015)
TCT-699 The Italian DFM Registry: real world results of a next generation fully repositionable TAVI device
Authors: Federico De Marco, Nicola Buzzatti, Giuseppe Bruschi, Neil Ruparelia, Gaetano Contegiacomo, Carlo Trani, Francesco Bedogni, Stefano Nava, Francesco Burzotta, Luca Testa, Gian Paolo Ussia, Nedy Brambilla, Mauro De Benedictis, Antonio Colombo, Azeem Latib
Journal: Journal of the American College of Cardiology (2015)
Randomized comparative evaluation of endoscopic submucosal dissection self-learning software in France and Japan
Authors: Mathieu Pioche, Jérôme Rivory, Toshihiro Nishizawa, Toshio Uraoka, Sandrine Touzet, Marc O’Brien, Jean-Christophe Saurin, Thierry Ponchon, Angélique Denis, Naohisa Yahagi
Journal: Endoscopy (2016)

<b>Background and study aim:</b> Endoscopic submucosal dissection (ESD) is currently the reference method to achieve an en bloc resection for large lesions; however, the technique is difficult and risky, with a long learning curve. In order to reduce the morbidity, training courses that use animal models are recommended. Recently, self-learning software has been developed to assist students in their training. The aim of this study was to evaluate the impact of this tool on the ESD learning curve. <b>Methods:</b> A prospective, randomized, comparative study enrolled 39 students who were experienced in interventional endoscopy. Each student was randomized to one of two groups and performed 30 ESDs of 30 mm standardized lesions in a bovine colon model. The software group used the self-learning software whereas the control group only observed an ESD procedure video. The primary outcome was the rate of successful ESD procedures, defined as complete en bloc resection without any perforation and performed in less than 75 minutes. <b>Results:</b> A total of 39 students performed 1170 ESDs. Success was achieved in 404 (70.9 %) in the software group and 367 (61.2 %) in the control group (<i>P</i> = 0.03). Among the successful procedures, there were no significant differences between the software and control groups in terms of perforation rate (22 [4.0 %] vs. 29 [5.1 %], respectively; <i>P</i> = 0.27) and mean (SD) procedure duration (34.1 [13.4] vs. 32.3 [14.0] minutes, respectively; <i>P</i> = 0.52). For the 30th procedure, the rate of complete resection was superior in the software group (84.2 %) compared with the control group (50.0 %; <i>P</i> = 0.01). <b>Conclusion:</b> ESD self-learning software was effective in improving the quality of resection compared with a standard teaching method using procedure videos. This result suggests the benefit of incorporating such software into teaching programs.
Proteasome Inhibitors Restore to Normal the Decreased Levels of Protein Expression and Nucleolar Localization of Various Mutant Ribosomal S19 Proteins Identified in DBA Patients.
Authors: Aurore Cretien, Alexis Proust, Hanna Gazda, Jorg Meerpohl, Charlotte Marie Niemeyer, Jean Delaunay, Gil Tchernia, Mohandas Narla, Lydie Da Costa
Journal: Blood (2005)
MS4A3 Improves Imatinib Response and Survival in BCR-ABL1 Primary TKI Resistance and in Blastic Transformation of Chronic Myeloid Leukemia
Authors: Anna M. Eiring, Jamshid S. Khorashad, Anupriya Agarwal, Clinton C. Mason, Fan Yu, Hannah M. Redwine, Amber D. Bowler, Kevin C. Gantz, Kimberly R. Reynolds, Phillip M. Clair, David J. Anderson, Srinivas K Tantravahi, Shannon K. McWeeney, Brian J. Druker, Derek L. Stirewalt, Vivian G. Oehler, Thomas O'Hare, Michael W. Deininger
Journal: Blood (2015)
Molecular genetic subgroups of pediatric B-lineage acute lymphoblastic leukemia: A single institutional experience from India
Authors: S. P. Yadav, N. Radhakrishnan, M. Anjan, A. Sachdeva
Journal: Journal of Clinical Oncology (2008)

10045 Background: Chromosomal abnormalities have important diagnostic and prognostic significance in acute lymphoblastic leukemia (ALL). Precursor B cell ALL with t(12; 21) (TEL/AML1) is the most common genetic subtype of ALL in children in the 2–10 years age group. Unlike in adults the frequency of BCR/ABL fusion in children with ALL is less than 5%. It has been postulated that geographic and racial variations exist among different genetic subgroups of ALL. The frequency of TEL/AML fusion has been to the tune of 25 - 35% in data available from USA, Italy, Germany and France. Previous studies have shown a very low frequency (0–8.6%) of TEL/AML in Indian patients. Methods: 42 patients of ALL were diagnosed in the study period of 1 year (2007) out of which 36 patients were of B lineage. 3 cases were T cell leukemia and one was biphenotypic leukemia. All were subjected to conventional cytogenetic evaluation of bone marrow. Among them only 27 samples could be sent for molecular studies due to monetary constraints. These samples were sent for Interphase FISH analysis to determine the presence of t(12; 21) and t(9; 22). LSI TEL/AML1 probe was used for t(12; 21) and LSI bcr/abl was used for t (9; 22). Many of these cases had normal cytogenetic study on conventional karyotyping. Results: The median age of this group of 27 patients was 4.5 years. Male:Female ratio was observed to be 1.4:1. 25 cases were immunophenotypically of Precursor B lineage. One was a case of Infant ALL and another was biphenotypic leukemia. t(12; 21) was observed in 3 out of 27 cases (11%) studied. t(9; 22) was seen in 2 cases (7.4%). One patient was a case of infant leukemia and had MLL gene rearrangement (46 XY ins (19:11) (p13; q13q23). The frequency of t(12; 21) even though is low (11%) compared to western data, is marginally higher when compared to previous Indian studies. Conclusions: Lower incidence of TEL/AML1 may be a contributory factor to poor results seen in the Indian subcontinent. This also emphasizes that molecular study using FISH and RT-PCR should be done even when conventional cytogenetics is reported as normal. No significant financial relationships to disclose.
Phase I Study of Vorinostat in Combination with Decitabine in Patients with Relapsed or Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Authors: Mark Kirschbaum, Ivana Gojo, Stuart L Goldberg, Lisa Kujawski, Ehab Atallah, Peter Marks, Jose Garcia- Vargas, Syed Rizvi, Donna Di Gravio, Janet Ahern, Jean-Pierre Issa
Journal: Blood (2008)
C-Myc Mediated Regulation of Multidrug Resistance Genes in Chronic Myeloid Leukaemia Cd34+ Cell Progenitors.
Authors: Samuele Gherardi, Simona Soverini, Nunzio Iraci, Carolina Terragna, Emanuele Valli, Sandra Durante, Annalisa Astolfi, Roberto Bernardoni, Thea Kalebic, Fabrizio Pane, Giuseppe Saglio, Giovanni Martinelli, Michele Baccarani, Giovanni Perini
Journal: Blood (2009)
Five things we have learnt about doctors’ careers
Authors: Abi Rimmer
Journal: BMJ (2016)

The BMA has published its 10th cohort study of doctors who graduated in 2006.1 These were among the findings of the survey of 430 doctors, conducted in 2015

Nine years after graduation, 42% of the doctors said that they planned to practise medicine overseas, up from 37% in 2014. Male doctors were more likely to want to work overseas, …
Prognostic Significance of CD33, CD34 and CD117 Expression on Bone Marrow Blasts of Patients with Myelodysplastic Syndromes.
Authors: Guido Nador, Alfredo Molteni, Clara Cesana, Michele Nichelatti, Barbara Scarpati, Roberto Cairoli, Luciana Barbarano, Annamaria Nosari, Enrica Morra
Journal: Blood (2007)